The document discusses a new hypothesis for Alzheimer's disease (AD) treatment, focusing on homocysteic acid (HA) as a pathogen. It reports on the development of HBF brain food, which can recover cognitive impairment in AD patients by reducing HA levels in the blood. An open clinical trial with 61 patients showed significant cognitive improvement after consuming HBF brain food for two months.
documents/EFTA01193574.pdf
{}